Anti-IL-17A (Taltz) (Ixekizumab biosimilar) mAb, IgG4, Human Humanized, Monoclonal
Biozol Catalog Number:
ABI-12-2002
Supplier Catalog Number:
12-2002
Alternative Catalog Number:
ABI-12-2002-100UG
Manufacturer:
Abeomics
Host:
Human Humanized
Category:
Antikörper
Application:
ELISA
Species Reactivity:
Human
Ixekizumab/ Anti-IL-17A (Taltz) is a humanized IgG4 biosimilar monoclonal antibody expressed by mammalian cell lines that block the biological activity of IL-17A. IL-17A is a pro-inflammatory cytokine that triggers immune cells like neutrophils, lymphocytes, macrophages, monocytes, natural killer (NK) cells, and B cells that play essential roles in innate and adaptive immune responses. IL-17A binds IL17RA-IL17RC heterodimeric receptor complex to activate TRAF6 and NF-kappaB pathway, leading to pro inflammatory cytokines and chemokines gene expression. The Ixekizumab biosimilar developed by Abeomics is a high-quality research grade biosimilar and is not to be used for therapeutic or diagnostic procedures for humans and animals.
Clonality:
Monoclonal
Isotype:
IgG4
Purity:
Purified from cell culture supernatant by affinity chromatography
Application Dilute:
ELISA 1:5000-10000, FACS 1:100
* VAT and and shipping costs not included. Errors and price changes excepted
